Compare Amphastar Pharmaceuticals Inc (AMPH) vs FuelCell Energy Inc (FCEL) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FuelCell Energy (FCEL) trades at $21.03, down 8.57% amid recent volatility from a $225 million stock offering. The stock shows a bullish technical signal with moving averages supporting an uptrend, while oscillators remain neutral. Fundamentally, the company continues to report losses with a net income margin of -132.41% in 2025, though revenue grew to $158.16 million. Recent news highlights a strategic partnership with Siemens to scale clean power solutions for data centers, a key growth area representing 90% of its sales pipeline.

FCEL presents a high-risk, high-reward opportunity driven by AI data center demand and new partnerships, but persistent profitability challenges and shareholder dilution from recent financing pose significant risks. Analyst consensus is mixed with a $20.13 price target, suggesting cautious optimism amid ongoing operational losses and competitive pressures in the fuel cell sector.